Home/Pipeline/DeFluvac

DeFluvac

Seasonal Influenza

CommercialActive

Key Facts

Indication

Seasonal Influenza

Phase

Commercial

Status

Active

Company

About BioDiem

Australian biotech licensing LAIV influenza vaccine technology for global partners.

View full company profile

Therapeutic Areas

Infectious Diseases

Other Seasonal Influenza Drugs

Drug	Company	Phase	Status
Nasovac‑S™	BioDiem	Commercial	Active
Vaxine Flu Vaccine	Vaxine	Phase 2/3	Active
MF59-Adjuvanted Seasonal Vaccines	CSL Seqirus	Marketed	Lifecycle Management
Flucelvax Quadrivalent (cell-based)	CSL Seqirus	Marketed	Lifecycle Management
Flublok Quadrivalent (recombinant)	CSL Seqirus	Marketed	Lifecycle Management
Aramis FluVac	Aramis Biotechnologies	Preclinical	Active
mRNA-based Influenza Vaccine	Sanofi	Phase 3	Active
mRNA-1010/1011	Moderna	Phase 3	Active
Standalone Seasonal Influenza Vaccine	Novavax	Phase 3	Active
AdFlu‑Q	Adimmune	Preclinical	Active
LUNAR®-FLU (ARCT-2138)	Arcturus Therapeutics	Phase 1	Status Unknown
Oral Influenza Vaccine	Vaxart	Phase 2	Active